Evonik Reshuffles Six German Sites While Funding New Growth in Canada and Slovakia
Evonik is reshaping its global manufacturing footprint as it prepares for the next stage of its growth strategy through 2030.
The company plans to give its six major German production sites clearer strategic roles while using savings generated by its Evonik Tailor Made restructuring program to fund targeted growth projects in markets including Canada and Slovakia.
The strategy reflects a broader shift among specialty-chemical companies: reducing structural costs in mature European operations while directing investment toward higher-growth businesses, technologies, and regions.
From Cost Reduction to Targeted Growth
Evonik's strategy is built around a simple principle: reduce costs where the business structure is inefficient and redirect capital toward areas with stronger long-term growth potential.
The company says its Tailor Made program is creating financial flexibility for new investments.
The program includes:
Structural cost reductions
Workforce measures
Greater operational efficiency
Portfolio adjustments
Site consolidation
Digitalization and outsourcing opportunities
The second phase of Tailor Made is planned for 2027–2029, following the first phase covering 2024–2026.
Evonik expects approximately 3,200 additional jobs to be eliminated worldwide, including around 2,150 in Germany, as part of the second phase.
German Sites Get Clearer Strategic Roles
Rather than treating its German manufacturing network as a uniform footprint, Evonik plans to define a specific role for each of its six major production sites.
The objective is to:
Concentrate production where scale is strongest
Reduce fragmented structures
Improve utilization
Strengthen competitiveness
Accelerate innovation
Improve customer supply reliability
The company is also closing smaller sites where long-term economic prospects are insufficient.
For example, Evonik plans to close its Hamburg site, which supplies products for cosmetics and personal care, and its Bitterfeld site, which produces chlorosilanes. Activities from these locations will be concentrated at larger sites. (evonik.com)
This distinction is important: Evonik is restructuring and concentrating its German footprint, rather than simply withdrawing from Germany.
Canada and Slovakia Become Growth Destinations
At the same time, Evonik is increasing investment outside Germany.
The company has launched healthcare and biotechnology growth projects in Canada and Slovakia, with a combined investment volume in the three-digit-million-euro range.
The move supports Evonik's goal of achieving a more balanced regional footprint across:
Europe
Asia
The Americas
Evonik says it sees particularly strong growth opportunities in Asia and the Americas while continuing to use its European manufacturing network to serve international markets. (evonik.com)
Slovakia Strengthens Biotechnology Capabilities
The Slovakian investment is particularly relevant to Evonik's healthcare strategy.
At its Fermas site in Slovenská Ľupča, Evonik has started an approximately €80 million biotechnology expansion.
The project will add downstream fermentation technology and increase capacity for developing and manufacturing complex pharmaceutical intermediates.
Completion is expected in early 2028 and the expansion is expected to create around 50 new jobs. (evonik.com)
The investment strengthens Evonik's precision-fermentation and contract-manufacturing capabilities, making Slovakia an increasingly important part of its biotechnology network.
North America Is Also Becoming More Important
Evonik's broader asset-balancing strategy also includes substantial investment in North America.
In July 2026, the company announced a US$100 million investment over five years to modernize its Tippecanoe Labs drug-substance manufacturing site in Lafayette, Indiana.
The investment is intended to expand capabilities for complex active pharmaceutical ingredients and meet growing demand for U.S.-based contract development and manufacturing services.
Together with the Canadian growth projects, the investment demonstrates how Evonik is increasing the strategic importance of the Americas within its global manufacturing network. (evonik.com)
Portfolio Strategy Is Changing Too
The restructuring is not limited to manufacturing locations.
Evonik is also organizing businesses according to strategic roles, including:
Growth Drivers
Businesses expected to benefit from attractive structural markets and technological opportunities.
Cash Generators
Established businesses expected to generate reliable cash while operating with disciplined capital allocation.
The company is also establishing a new Designed Polymer Solutions business line covering growth areas such as aerospace, automotive, gas separation, biogas, and hydrogen.
This approach allows Evonik to concentrate capital and management attention on businesses where it sees stronger long-term opportunities.
Why the Strategy Matters for Specialty Chemicals
Evonik's restructuring provides a useful example of how specialty-chemical companies are responding to difficult European market conditions.
The industry continues to face:
Weak demand
High structural costs
International competition
Lower-cost Asian production
Pressure on margins
Uneven capacity utilization
Changing regional economics
Evonik's response is to combine cost reduction, site concentration, portfolio management, and targeted growth investment rather than relying solely on broad-based capacity expansion.
Competitive Intelligence
Chemical companies and procurement teams should monitor several indicators as Evonik implements its strategy.
1. Site Consolidation
Closures and production transfers can change regional availability and supplier lead times.
2. New Capacity
Investments in healthcare, biotechnology, and advanced technologies can signal future growth markets.
3. Regional Balance
Capital moving toward North America and Asia may indicate where specialty-chemical demand is expected to strengthen.
4. Portfolio Changes
Business divestments and new business lines can alter supplier relationships and product ownership.
5. Capacity Utilization
Consolidation can improve utilization at larger sites while reducing fragmented production.
Procurement Considerations
Procurement teams should monitor Evonik's restructuring because site changes can influence supply-chain configurations even when products remain within the company's portfolio.
Key considerations include:
Manufacturing-site changes
Product transfer announcements
Regional production capacity
Lead times
Contract continuity
Regulatory documentation
Alternative suppliers
Inventory requirements
Customer qualification requirements
For critical specialty chemicals, procurement teams should distinguish between a site closure, production transfer, business divestment, and temporary capacity reduction, as each can have different supply implications.
Looking Ahead
Evonik's strategy shows how specialty-chemical companies are increasingly treating manufacturing footprints as strategic assets rather than fixed infrastructure.
The company is reducing structural complexity in Germany while directing capital toward healthcare, biotechnology, advanced technologies, and selected international growth markets.
The success of the strategy will depend on whether cost savings can be converted into stronger returns from the targeted growth businesses.
For chemical buyers, the key issue will be how these changes affect production locations, capacity, product availability, and regional supply resilience over the next several years.
Key Takeaways
Evonik is giving its six major German production sites clearer strategic roles as part of its transformation through 2030.
The Tailor Made program is being used to create financial flexibility for targeted growth investments.
A second restructuring phase will run from 2027 to 2029 and includes around 3,200 additional job reductions globally.
Healthcare and biotechnology projects in Canada and Slovakia represent a three-digit-million-euro investment.
Evonik is also strengthening North American healthcare manufacturing through a US$100 million Tippecanoe Labs investment.
Site consolidation and portfolio restructuring could change regional supply patterns for specialty chemicals.
Procurement teams should monitor production transfers, site closures, capacity changes, and supplier-qualification requirements.
Sources
Benzoic Acid
Found this useful?
